These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19029327)

  • 1. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.
    Damle BD; Dowell JA; Walsky RL; Weber GL; Stogniew M; Inskeep PB
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1149-56. PubMed ID: 19029327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin.
    Ong V; Hough G; Schlosser M; Bartizal K; Balkovec JM; James KD; Krishnan BR
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6872-6879. PubMed ID: 27620474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
    Estes KE; Penzak SR; Calis KA; Walsh TJ
    Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anidulafungin: review of a new echinocandin antifungal agent.
    Raasch RH
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):499-508. PubMed ID: 15482216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.
    Ong V; James KD; Smith S; Krishnan BR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450.
    Niwa T; Imagawa Y; Yamazaki H
    Curr Drug Metab; 2014; 15(7):651-79. PubMed ID: 25429674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
    Kuti EL; Kuti JL
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1287-300. PubMed ID: 20822479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin].
    Catalán González M; Montejo González JC
    Rev Iberoam Micol; 2008 Jun; 25(2):92-100. PubMed ID: 18473503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Marker of Echinocandin Activity in an
    Meletiadis J; Siopi M; Tsakris A; Mouton JW; Pournaras S
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Potential of anidulafungin in hematological patients].
    Vázquez López L; Ruiz Camps I
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():44-50. PubMed ID: 19572434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties.
    James KD; Laudeman CP; Malkar NB; Krishnan R; Polowy K
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin: an echinocandin antifungal.
    Pfaller MA
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1183-97. PubMed ID: 15330749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anidulafungin: a novel echinocandin.
    Vazquez JA; Sobel JD
    Clin Infect Dis; 2006 Jul; 43(2):215-22. PubMed ID: 16779750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins].
    Azanza JR; Montejo M
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():14-20. PubMed ID: 19572430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
    Dowell JA; Stogniew M; Krause D; Henkel T; Weston IE
    J Clin Pharmacol; 2005 Feb; 45(2):227-33. PubMed ID: 15647416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
    Dowell JA; Knebel W; Ludden T; Stogniew M; Krause D; Henkel T
    J Clin Pharmacol; 2004 Jun; 44(6):590-8. PubMed ID: 15145966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
    Andes D; Diekema DJ; Pfaller MA; Prince RA; Marchillo K; Ashbeck J; Hou J
    Antimicrob Agents Chemother; 2008 Feb; 52(2):539-50. PubMed ID: 18070979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro activity of anidulafungin. Comparison with the activity of other echinocandins].
    Martín Mazuelos E; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():7-13. PubMed ID: 19572429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.